Table 3 Summary of the interventions
Anticoagulant groups | Incidence of adverse events (total) | Relative risk adverse event (95% CI) | Number of participants (studies) | |
|---|---|---|---|---|
Group A (%) | Group B (%) | |||
Continuation of anticoagulants (group A) vs no anticoagulant (group B) | 29 (8.1) | 35 (3.0) | 2.30 [1.25, 4.24] | 1384 (6) |
Pause of anticoagulant (group A) vs no anticoagulant (group B) | 8 (19.5) | 2 (4.7) | 1.45 [0.22, 9.70] | 83 (2) |